|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 180.92 AUD | +1.96% |
|
-10.83% | -18.09% |
| 30/12 | Pro Medicus Chairman Acquires 600 Ordinary Shares | MT |
| 04/12 | Pro Medicus gives response to speculation | RE |
| Capitalization | 18.9B 12.98B 11.04B 10.24B 9.57B 17.83B 1,193B 117B 46.44B 563B 48.69B 47.69B 2,049B | P/E ratio 2026 * |
119x | P/E ratio 2027 * | 89.1x |
|---|---|---|---|---|---|
| Enterprise value | 18.66B 12.82B 10.9B 10.11B 9.44B 17.61B 1,178B 116B 45.86B 556B 48.07B 47.09B 2,023B | EV / Sales 2026 * |
65.4x | EV / Sales 2027 * | 50x |
| Free-Float |
48.8% | Yield 2026 * |
0.42% | Yield 2027 * | 0.56% |
Last Transcript: Pro Medicus Limited
| 1 day | +1.96% | ||
| 1 week | -10.83% | ||
| Current month | -18.09% | ||
| 1 month | -22.07% | ||
| 3 months | -35.80% | ||
| 6 months | -44.16% | ||
| Current year | -18.09% |
| 1 week | 171.45 |  | 200.99 |
| 1 month | 171.45 | | 227.4 |
| Current year | 171.45 | | 223.02 |
| 1 year | 161.64 | | 336 |
| 3 years | 58.6 | | 336 |
| 5 years | 36.54 | | 336 |
| 10 years | 2.67 | | 336 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sam Hupert
CEO | Chief Executive Officer | - | 01/10/2010 |
Anthony Hall
CTO | Chief Tech/Sci/R&D Officer | - | - |
Clayton Hatch
DFI | Director of Finance/CFO | - | 01/07/2012 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Hall
BRD | Director/Board Member | - | 01/01/1983 |
Peter Kempen
CHM | Chairman | 75 | 01/08/2010 |
Anthony Glenning
BRD | Director/Board Member | - | 01/05/2016 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.07% | 0.01% | 33,076 M€ | |
| +3.72% | 0% | 32 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.96% | -10.83% | -33.05% | +186.13% | 12.98B | |
| -1.46% | -0.09% | -0.44% | +31.59% | 36.49B | |
| -0.71% | -3.13% | -10.66% | +36.19% | 4.77B | |
| +6.28% | +13.41% | - | - | 4.58B | |
| -4.00% | -13.46% | - | - | 2.74B | |
| -5.53% | -9.11% | - | - | 2.67B | |
| -1.99% | -0.44% | +16.52% | -12.99% | 2.26B | |
| +2.66% | -7.49% | +7.33% | - | 1.46B | |
| +2.48% | -2.36% | +45.96% | -38.84% | 1.28B | |
| Average | -0.03% | -2.55% | +4.28% | +40.42% | 7.69B | |
| Weighted average by Cap. | -0.37% | -2.17% | -6.56% | +63.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 285M 196M 167M 155M 144M 269M 18.01B 1.77B 701M 8.5B 735M 720M 30.93B | 372M 255M 217M 201M 188M 351M 23.45B 2.3B 913M 11.07B 957M 937M 40.27B |
| Net income | 159M 109M 92.71M 85.93M 80.3M 150M 10.01B 982M 390M 4.73B 409M 400M 17.2B | 212M 145M 124M 115M 107M 200M 13.35B 1.31B 520M 6.3B 545M 534M 22.93B |
| Net Debt | -239M -164M -140M -130M -121M -226M -15.1B -1.48B -588M -7.13B -616M -604M -25.93B | -340M -234M -199M -184M -172M -321M -21.47B -2.11B -836M -10.14B -876M -858M -36.87B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 180.92 $ | +1.96% | 312,961 |
| 22/01/26 | 177.45 $ | -0.52% | 331,926 |
| 21/01/26 | 178.37 $ | -4.38% | 349,212 |
| 20/01/26 | 186.55 $ | -1.35% | 577,645 |
| 19/01/26 | 189.10 $ | -6.80% | 220,264 |
Delayed Quote Australian S.E., 23 January 2026 at 04:10 pm AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PME Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition